Olympia sermorelin review: injection listings, pricing, and inspection context

What the sermorelin listing actually says

The current injection page lists sermorelin acetate at a concentration of 0.9 milligrams per milliliter. Its catalog includes intramuscular and subcutaneous routes and directs readers to a licensed clinician for dosing advice. The listed concentration tells you how much drug is present in a volume; it is not a patient’s dose.

The route for an individual prescription must come from the prescriber and dispensing label. A page showing two routes does not mean a patient can choose between them, switch independently, or use instructions from another brand. Our injection guide explains the training and clarification that should come before use.

Ask whether the product your clinic proposes matches the current catalog, and request its exact ingredients, concentration, volume, and container type. If a refill differs, the pharmacist should explain the change before you rely on familiar syringe markings. The measurement guide separates concentration from dose and syringe units.

What an NAD+ bundle does and does not establish

Olympia’s NAD+ and sermorelin bundle page advertises both injectable products. A bundle listing is evidence of an offering. It is not a controlled clinical study showing that the combination provides better outcomes than either treatment, or than an established alternative for the patient’s actual condition.

The word “bundle” also does not establish that ingredients are mixed in one vial or should be combined in one syringe. Ask what is supplied, whether there are separate prescriptions and instructions, and how the clinician justifies each component. Do not create a mixing protocol from the catalog description.

Our sermorelin and NAD+ comparison explains the different substances and the limits of combination claims. If two products are proposed together, the treatment plan should still identify a measurable purpose for each and explain how new symptoms will be evaluated.

Keep fitness marketing separate from clinical outcomes

A pharmacy’s explanation of growth-hormone signaling can be useful background. It does not establish that its finished preparation improves strength, recovery, sleep, or healthy lifespan in the person reading the page. Ingredient research needs to be matched to the formulation, route, patient group, and outcome being discussed.

For an adult over 50, an increase in a hormone marker is not the same as walking more comfortably, maintaining strength, or sleeping better. Ask what benefit is realistically being pursued and how it will be assessed. The benefits and evidence guide helps distinguish biological effects from patient-relevant results.

We did not identify a product-specific clinical trial in the reviewed catalog material that establishes all the advertised uses of the injection or the bundle. That describes the limits of this review; it is not a claim that no relevant research could exist elsewhere. A prescriber should be able to discuss the strongest applicable evidence and its limitations.

Read the 2025 inspection document accurately

The FDA publishes a Form 483 for its August 2025 inspection of Olympia Pharmaceuticals at 6700 Conroy Road, Suite 155, Orlando. The inspection ran from July 28 through August 8, 2025; the linked document includes Amendment 1, issued August 12. The document records observations involving procedures intended to prevent microbiological contamination, including concerns about aseptic-process validation and airflow assessment.

Those are relevant quality questions for someone evaluating a sterile compounded product. They should be discussed using the actual document, facility, and date. The FDA’s Form 483 explanation states that inspection observations do not represent a final agency determination.

The document does not prove that an individual sermorelin vial was contaminated. It also does not establish current corrective-action status. This review has not audited the facility’s response or independently tested a lot. Ask the pharmacy for current information addressing the observations and confirm whether this is the operation involved in your prescription.

Verify the pharmacy behind your order

A clinic brand and a dispensing pharmacy perform different roles. A catalog logo cannot confirm the relationship for every patient, state, and formulation. Request the pharmacy’s full legal name, address, contact number, and the preparation that will actually be dispensed.

Use the FDA’s state-board directory to check the relevant licensing information. Our review did not independently verify every state license or determine which facility would supply a hypothetical order. The compounding pharmacy guide explains why the exact entity matters more than a general statement about a company.

An outsourcing-facility designation does not make a compounded drug FDA-approved. The FDA’s compounding framework and its finished-drug approval process are different. A patient should be able to ask about both regulatory status and practical quality controls without receiving a marketing badge as the entire answer.

Compare the full bill, not a catalog impression

The pages reviewed did not establish a universal all-inclusive cash price for a patient’s treatment. What you pay may depend on the prescribing program, quantity, formulation, consultation, laboratory work, shipping, supplies, and follow-up. A bundle can also change the total without clarifying whether both components are necessary.

Ask for a written breakdown of the first payment and recurring payments. Confirm how many supplies are included, whether laboratory work is billed separately, and which cancellation or refund terms apply. A program should explain the financial outcome if treatment is not prescribed or later becomes inappropriate.

Use the sermorelin cost worksheet to compare the same time period and included services. A lower advertised monthly number does not establish a lower total, and a higher price does not prove better clinical results or product quality.

Plan for delivery questions and follow-up

Read the dispensing label before using the product. Confirm the route, prescribed amount, storage instructions, and beyond-use date. If there is a shipping concern or the packaging does not match what you were told to expect, contact the pharmacist with the label and delivery details available.

Do not estimate suitability from appearance alone or replace product-specific instructions with a general internet rule. Ask who handles a temperature concern, missing supplies, or a suspected adverse effect, and how the clinic and pharmacy coordinate. The storage and travel guide explains why an individual preparation needs its own instructions.

What would make the decision clearer

Olympia’s public pages identify an injectable option and a bundle, while the FDA record supplies dated inspection context that should be considered fairly. A useful review cannot turn either source into a guarantee about a particular patient’s outcome or a particular lot.

Before enrolling, get the exact product, complete price, responsible professionals, and current quality information in writing. The Empower pharmacy review offers another pharmacy-specific comparison. Use these details to assess the proposed care process and the remaining uncertainties, rather than choosing solely by a catalog claim or a star rating.